drugset / Trial / NCT07815665
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)
Timeline
- Start
- 2026-09-10
- Primary completion
- 2030-10-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Background | Enfortumab Vedotin | Other / unclassified | — | — |